ENGINEERED IMMUNE CELL EXPRESSING NK INHIBITORY MOLECULE AND USE THEREOF
Provided is an NK inhibitory molecule, which includes one or more NK inhibitory ligands, a transmembrane domain and a co-stimulatory domain, wherein the NK inhibitory ligand specifically binds to NK inhibitory receptors to inhibit the killing of NK cells against the engineered immune cells expressing the NK inhibitory molecule. Also provided is an engineered immune cell expressing the NK inhibitory molecule of the present invention, wherein the expression of at least one MHC-related gene is suppressed or silenced. Further provided is the use of the engineered immune cell in the treatment of cancers, infections or autoimmune diseases. Compared to the traditional engineered immune cells, the engineered immune cell can significantly inhibit the killing effect of NK cells in a subject, thereby reducing the risk of HvGD..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 28. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHOU YALI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-28, Last update posted on www.tib.eu: 2024-03-07, Last updated: 2024-03-08 |
|---|
| Patentnummer: |
EP4112721 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016469992 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016469992 | ||
| 003 | DE-627 | ||
| 005 | 20240308101624.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016469992 | ||
| 035 | |a (EPA)EP4112721 | ||
| 035 | |a (EPA)78893017 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHOU YALI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ENGINEERED IMMUNE CELL EXPRESSING NK INHIBITORY MOLECULE AND USE THEREOF |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-28, Last update posted on www.tib.eu: 2024-03-07, Last updated: 2024-03-08 | ||
| 520 | |a Provided is an NK inhibitory molecule, which includes one or more NK inhibitory ligands, a transmembrane domain and a co-stimulatory domain, wherein the NK inhibitory ligand specifically binds to NK inhibitory receptors to inhibit the killing of NK cells against the engineered immune cells expressing the NK inhibitory molecule. Also provided is an engineered immune cell expressing the NK inhibitory molecule of the present invention, wherein the expression of at least one MHC-related gene is suppressed or silenced. Further provided is the use of the engineered immune cell in the treatment of cancers, infections or autoimmune diseases. Compared to the traditional engineered immune cells, the engineered immune cell can significantly inhibit the killing effect of NK cells in a subject, thereby reducing the risk of HvGD. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CHEN GONG |4 aut | |
| 700 | 0 | |a JIANG XIAOYAN |4 aut | |
| 700 | 0 | |a REN JIANGTAO |4 aut | |
| 700 | 0 | |a HE XIAOHONG |4 aut | |
| 700 | 0 | |a WANG YANBIN |4 aut | |
| 700 | 0 | |a HAN LU |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 28. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:28 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/78893017/publication/EP4112721A1?q=EP4112721 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 28 |c 02 | ||